Background: Home-based sampling is a strategy to enhance uptake of sexually transmissible infection (STI) screening. This review aimed to compare the screening uptake levels of home-based self-sampling and clinicbased specimen collection for STIs (chlamydia (Chlamydia trachomatis), gonorrhoea (Neisseria gonorrhoeae) and trichomoniasis) in females aged 14-50 years. Acceptability and effect on specimen quality were determined. Methods: Sixteen electronic databases were searched from inception to September 2012. Randomised controlled trials (RCTs) comparing the uptake levels of home-based self-sampling and clinic-based sampling for chlamydia, gonorrhoea and trichomoniasis in females aged 14-50 years were eligible for inclusion. The risk of bias in the trials was assessed. Risk ratios (RRs) for dichotomous outcomes were meta-analysed. Results: Of 3065 papers, six studies with seven RCTs contributed to the final review. Compared with clinic-based methods, home-based screening increased uptake significantly (P = 0.001-0.05) in five trials and was substantiated in a meta-analysis (RR: 1.55; 95% confidence interval: 1.30-1.85; P = 0.00001) of two trials. In three trials, a significant preference for home-based testing (P = 0.001-0.05) was expressed. No significant difference was observed in specimen quality. Sampling was rated as easy by a significantly higher number of women (P = 0.01) in the clinic group in one trial. Conclusions: The review provides evidence that home-based testing results in greater uptake of STI screening in females (14-50 years) than clinic-based testing without compromising quality in the developed world. Home collection strategies should be added to clinic-based screening programs to enhance uptake.
Introduction
According to the 2011 report by the World Health Organisation, over 440 million new treatable cases of chlamydia (Chlamydia trachomatis), gonorrhoea (Neisseria gonorrhoea) and Trichomonas vaginalis sexually transmissible infections (STIs), occur annually in those aged 15-49 years. 1 Due to physiological and social realities, higher burdens of these infections are recorded in female adolescents and young adults compared with their male counterparts. [2] [3] [4] [5] [6] [7] [8] [9] Over 50% of infections occur asymptomatically. Many are untreated, resulting in severe complications with adverse outcomes on maternal and child health. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In the developing world, with a greater burden, these infections and associated complications account for 17% of economic losses caused by ill health. [20] [21] [22] Mass screening of the at-risk population is one of several prevention and control strategies explored so far at local and international levels to stem the tide. [23] [24] [25] [26] [27] [28] Traditionally, the strategy utilised free clinic-based sampling and conventional culture methods for screening. 3, 12 Culture methods required specimen collection by a clinician in a pelvic examination, 15 which is often cited as a barrier to screening. [29] [30] [31] [32] Where a pelvic examination was not otherwise indicated, specimen collection by less invasive methods is sometimes preferred by women to avoid the physical embarrassment associated with undressing. [29] [30] [31] [32] [33] Following the incorporation of self-sampling (and molecular detection techniques) into clinic-based screening in several countries, access to clinic sites remains a major barrier. 30 Recent efforts to achieve greater control of STIs have centred on the use of home sampling to enhance uptake of screening. [34] [35] [36] [37] [38] The home-based testing strategy utilises a variety of selfcollected specimens (first void urine, vaginal swabs and tampons), molecular diagnostic systems, and self-pickup or mail delivery systems in screening for STIs. 39, 40 This method has been credited as having sensitivity and specificity levels that are on a par with clinic-based sampling utilising molecular detection techniques. 34, 41, 42 With accepted delivery periods ranging between 2 and 7 days, it offers privacy and flexibility in site of collection and delivery time. 40, 43, 44 Home sampling is thought to be minimally invasive, overcoming the barriers of unacceptability, fear and embarrassment associated with conventional screening methods. 33, [45] [46] [47] [48] Research has, however, thrown light on challenges with this strategy. 39, 49 One such challenge is the use of mail delivery, which could result in specimen loss, spillage, damage, late delivery and a need for rescreening. 39, 49 Besides, mail delivery of specimens is currently prohibited in some countries. 30, 49 In two Danish studies, a home-based strategy was considered more effective than clinic-based testing in women. 24, 36 This finding contrasted with two other studies on effectiveness in Brazil and USA. 31, 49 The surge in the incidence of STIs over the past decade, 9, 37, 50 has called into question the efficacy and perceived success of existing control strategies and brought to light the need for a focus on effective interventions.
This study examined the effectiveness of home-based sampling strategies on increasing the uptake of STI screening programs in females aged 14-50 years and their impact on specimen quality compared with traditional clinic screening. It was undertaken to inform population-level screening programs in both industrialised and developing countries, as well as to contribute to the pool of research evidence on effectiveness.
Methods
Sixteen electronic bibliographic databases comprising biomedical, scientific (e.g. Cochrane Library, MEDLINE, EMBASE, CINAHL,ASSIA, PSYc INFO, Web of Science, CRD and ongoing clinical trial registries) and grey literature sources were searched from inception to September 2012.
The search strategy utilised thesaurus and free text terms representative of both population and intervention (e.g. STI, chlamydia, gonorrhoea, trichomoniasis, venereal disease, home-based sampling, screening) with Boolean operators to ensure the maximal yield of all relevant articles. 51 These were then combined with validated RCT filters. Electronic searches were further supplemented with hand searches of STI journals. A reference manager (RefWorks ver. 2.0, ProQuestLLC, Ann Arbor, MI, USA) was used to identify and eliminate duplicates. Citations were sifted by title, abstract and full text. A description of the search strategy and potentially relevant studies excluded from the review are depicted in a flowchart. 52 
Inclusion and exclusion criteria
Study selection was undertaken by two reviewers using the following inclusion criteria: 51 RCTs were chosen to limit confounding and bias that could mask the true measure of effect of an intervention. 51 RCTs comparing home-based selfsampling (by mail or self-pickup delivery) and clinic-based testing strategies (by clinician or self) for the selected STIs: chlamydia (Chlamydia trachomatis), gonorrhoea (Neisseria gonorrohoea) or trichomonas in females aged 14-50 years were considered eligible for review. All eligible trials utilised validated molecular detection methods for diagnosing STIs.
The primary outcome of interest was uptake or non-uptake of screening, defined as the number of females screened as a proportion of all those that should have been screened. 53 Secondary outcomes were number of rejected samples, preference for and ease of self-sampling. RCTs utilising other populations (males, children or animals), and non-English and non-randomised studies were excluded.
Data abstraction
Data relating to study design, quality and results were extracted directly to customised electronic data extraction forms in a bid to avoid transcription errors. Where multiple publications of a study existed, data were extracted and reported as one study.
Quality assessment strategy
Two reviewers assessed the quality of trials utilising the Cochrane risk of bias tool. 51 The mode of sequence generation, allocation concealment, blinding of participants and assessors, incomplete outcome data and selective reporting, as well as other study specific forms of bias, were assessed. 51 Quality assessors were not blinded to author, institution or journal.
Data synthesis
For each study, relevant data were highlighted by means of descriptive tables. 54, 55 A meta-analysis was achieved with Review Manager ver. 5.1.2 (Java 6, The Cochrane Collaboration, Copenhagen, Denmark) for dichotomous outcomes providing the number of events per number of participants in each trial arm. 51 A random effect model was assumed for all analysis accounting for between-study variation, and providing wider and more conservative estimates than the fixed effect model. 51, 56 Uptake was reported as a risk ratio (RR) and a 95% confidence interval (CI). 51 An assessment of heterogeneity was performed on studies utilised in a meta-analysis using the I 2 method as described in the Cochrane Handbook. 51 The I 2 test is designed to quantify inconsistency across studies as well as to assess the impact of such heterogeneity on the metaanalysis. 51, 56 Substantial levels of heterogeneity (I 2 levels >50%) were explored with a sensitivity analysis assessing the effect of bias and study design. 51, 56 It was hypothesised that mode of assessment (medical records ver. medical records plus self-report), organisational factors in the health systems of developed versus developing countries and study duration ( 12 months and >12 months) may impact on outcome. 56 A subgroup analysis was achieved by mode of assessment, study duration and continent. Where a meta-analysis was considered inappropriate (e.g. unit of analysis issues in cluster trials, insufficient data or type of outcome), a narrative synthesis was done to present results.
Results
A PRISMA flow chart 52 depicting the process of identifying relevant RCTs is depicted in Fig. 1 . Six RCTs of long-and shortterm duration were included in the study. A summary of each study is presented in Table 1 .
All RCTs were published between 1998 and 2011 ( Table 1 ). In total, 5475 females between the ages of 14 to 45 years 57,58 (mean age: 21.6 years) were enrolled in the trials. The number of participants in each trial ranged from 420 59 to 1761. 60 The home and clinic groups had 2774 (50.7%) and 2701 (49.3%) females allocated to each respectively. 49, [57] [58] [59] [60] [61] Four of the six trials were conducted in developed countries. [58] [59] [60] [61] Recruitment of participants was from both the clinic and the community in four studies, 49, 57, 59, 61 one from multiple clinics 58 and another from schools. 60 Females were either sexually active, 59-61 on long-acting contraceptives, 58 had a prior history of an STI screen or had completed a baseline screen as a prerequisite for enrolment 61 in four studies. Literacy was used as a criterion for enrolment in two studies. 49, 57 Baseline demographic characteristics (age, marital status, socioeconomic status, ethnicity) were well balanced for both groups across the trials, with few exceptions. One trial 60 did not supply information on age, and two did not provide information on the comparability of ethnic groups between intervention and control groups. 57, 60 The trial by Graseck et al. 58 had more never married people in the clinic group, whereas Lippman et al. 49 had more single women in the home group.
Quality assessment
All trials documented the mode of sequence generation and had an at low risk for bias 49, [57] [58] [59] [60] [61] (Fig. 2 ). Randomisation was achieved at the cluster level in one trial. 60 Four of the trials utilised a parallel RCT design, 49, 58, 59 one used a factorial group (2 Â 2) design. 61 Four trials reported adequate methods of allocation concealment and were graded as having a low risk of bias. Two trials were graded as unclear due to insufficient documentation. 59, 60 As screening allocation cannot be blinded from patients and clinicians, and the mode of assessment is objective (determined by medical records, telephone interview or mailed survey), all trials were graded as having a low risk for detection bias. 49, [57] [58] [59] [60] [61] All trials were assessed as having dealt with missing data adequately. 49, [57] [58] [59] [60] [61] Three were at high risk of bias in that they did not give a complete report on one or more outcomes. 49, 58, 60 Other forms of bias like contamination and fulfilment of the power calculation were assessed across all the parallel trials. 49, [57] [58] [59] Three trials described the power calculation and met the required sample size for study. 49, 58, 59 A family planning clinic trial in the study by Xu et al. 61 failed to meet it due to a natural disaster (Hurricane Katrina) and was graded as highrisk. 61 The study by Lippman et al. was unclear. 49 Contamination between allocation groups was minimal (1%) in the study by Graseck et al. 58 The introduction of reminder calls also increased the potential for performance bias (with more reminder calls recorded for the home than for the clinic group) in two trials. 49, 61 These two trials were graded as having a high risk for bias. 49 The cluster trial by Ostergaard et al. 60 was at high risk for other forms of bias such as recruitment bias in that recruitment and consent were only obtained from participants after randomisation. 60 Furthermore, the lack of documentation of an intracluster correlation coefficient and power size calculation did not permit judgement as to whether a power size calculation was fulfilled. 60 Figs 3-6 show the forest plot with risk ratio for each study and pooled data. In two trials (1184 females) assessing uptake by a combination of self-report and medical records, a homebased self-sampling strategy significantly (RR: 1.55; 95% CI: 1.30-1.85; P = 0.00001) increased uptake of STI screening among females compared with clinic-based testing. Moderate but acceptable levels of heterogeneity (I 2 = 49%; c 2 = 1.96; P = 0.16) were observed between the two trials ( Fig. 3) .
In three trials (with 1987 females) assessing uptake via medical records (and providing sufficient data for a metaanalysis), no significant difference (RR: 1.37; 95% CI: 0.90-2.08; P = 0.14) was observed in the uptake of screening between women in the home and clinic groups. A high degree of heterogeneity (I 2 = 96%; c 2 = 44.50; P = 0.00001) was, however, observed between these trials (Fig. 3) . The test for heterogeneity was insignificant (I 2 = 0%; c 2 = 0.23; P = 0.63) when the trial by Graseck et al. 58 (utilising only clinic recruitment and a study duration of >12 months) was excluded from the analysis (Fig. 4) . The subgroup analysis was based on study duration (>12 months and 12 months) and continent, with the test for subgroup differences being significant (P < 0.0001). In the subgroups 12 months and developing country (measured by medical records), no significant difference (RR: 1.07; 95% CI: 1.00-1.14; P = 0.06) was observed in uptake of screening between women in the home and clinic groups (Fig. 4) .
The result from the subgroup analysis of 12 months was not in keeping with two other studies that measured outcome by medical records, but could not be meta-analysed due to insufficient data. 59, 60 The study by Cook et al. 59 assessed the proportion of women who completed at least one STI test within a 2-year period (three screen points) and found a significant increase (P = 0.001; 82.2% v. 61.3%) in uptake in favour of women in the home group compared with clinic group. 59 In that same study, more women in the home group were found to complete at least two tests in the 2-year period when compared with the clinic group (P = 0.001; 55.9% v. 37.2%). 59 Ostergaard et al.'s study, 60 a cluster trial analysed as an individual trial (unadjusted for clustering), also observed a statistically significant difference in the level of uptake in favour of females using home-based tests (P = 0.01; 867 out of 928 v. 63 out of 833). 60 Without an intracluster correlation coefficient, the results could not be adjusted for clustering and utilised in a meta-analysis.
Two studies measured the uptake of screening after the introduction of reminder calls. Figs 5, 6 shows the forest plots depicting the RR for each study and the pooled data. Following the introduction of reminders to encourage response in females, no significant difference (RR: 1.41; 95% CI: 0.81-2.44; P = 0.22) in uptake was observed between women in the home group and those in the clinic group. The trial by Lippman et al. 49 = 0.00; Chi z = 0.23, df = 1 (P = 0.63); l z = 0% Test for overall effect: Z = 1.88 (P = 0.06) Fig. 4 . Forest plot depicting the overall effect of the comparison between home-and clinic-based screening in relation to uptake (subgroup analysis). CI, confidence interval; M-H, Mantel-Haenszel.
(6 weeks) and enrolment criteria from the other two trials. 61 Applying a sensitivity analysis approach (Fig. 6 ) to the study design still resulted in substantial levels of heterogeneity (I 2 = 64%; c 2 = 2.76; P = 0.10), with subgroup analysis resulting in significant levels of uptake in favour of females in the home group (RR: 1.64; 95% CI: 1.17-2.30; P = 0.004).
The study by Xu et al. 61 limited the analysis to only participants reached by reminders. The meta-analysis resulted in a significant increase in uptake of screening in the home group (RR: 1.42; 95% CI: 1.18-1.70; P = 0.0002). The test for heterogeneity was not significant (P = 0.36). In the trial by Lippman et al., 49 introduction of reminder calls did not result Heterogeneity Tau z = 0.00; Chi z = 0.84, df = 1 (P = 0.36); l z = 0%
Test for overall effect: Z = 3.76 (P = 0.0002) Uptake (at 7 week window end of study) limited to those reached by reminders Heterogeneity, Tau z = 0.04; Chi z = 2.76, df = 1 (P = 0.10); l z = 64%
Test for overall effect: Z = 2.88 (P = 0.004) in a significant difference in uptake between participants in the home and clinic groups (RR:1.4; 95% CI: 0.81-2.44). In two studies, young age, being a student or having a high school education were important predictors of uptake. 49, 61 This contrasted with findings from a South African trial, where higher levels of uptake were observed among older women with a lack of education and multiple sexual partners. 57 Low socioeconomic status, 49 being of African-American descent 61 and a less frequent utilisation of clinics 59 were other notable predictors of uptake. Similar treatment follow-up rates were observed among women with positive tests allocated to either group. 49, [57] [58] [59] [60] [61] 
Secondary outcomes
Three trials considered secondary outcomes of interest: specimen quality, number of rejected specimens, 49,57,58 ease of self-sampling and a preference for home sampling. 49, 57, 58 Two 49,57 out of three trials reported no statistically significant differences in the number of specimens rejected between the intervention and control groups, with one study not providing enough data to permit judgement. 58 The ease of self-sampling was assessed in an ordinal fashion (via questionnaire) in three trials, preventing a metaanalysis. 49, 57, 58 In two trials, no significant difference was noted in response to a questionnaire on the ease of selfsampling in both the clinic and home groups, with all (100%) women reporting it as being easy. 49, 58 An exception was the trial by Jones et al., 57 where a significantly higher number of women (P < 0.01) in the clinic group (96.2% v. 85.8%) rated selfsampling as being easy. 57 A preference for home sampling (measured via questionnaires and interviews) was strongly associated with group allocation in the three trials. 49, 57, 58 In the three trials, 49, 58 
Discussion
This is the first systematic review comparing levels of screening uptake associated with home self-sampling and clinic-based sampling modalities of specimen collection for STI among females.
Home sampling resulted in an increased uptake of screening in five out of six studies. [57] [58] [59] [60] [61] This evidence was further substantiated in a meta-analysis of two trials 57,58 measuring uptake by self-report and in another involving trials measuring uptake (by medical records for >12 months) after the introduction of reminder calls. 61 A statistically significant effect demonstrated in one trial was found to vary with the mode of assessment of uptake. 57 The exclusion of self-report in the assessment in that trial resulted in an insignificant difference in uptake of screening between females in the home and clinic groups. 57 This trial was conducted in South Africa, where postal systems are not fully developed. 57 Consequently, considerable numbers of specimens submitted by women in the home group were reported as lost in the mail. 57 A similar finding was observed in another study in a low income country (Brazil). 49 In this study, no significant difference in uptake of screening was observed between women in the clinic and home group before and after the introduction of reminder calls (following a missed screen at Week 2) to enhance response rates. 49 A possible explanation for the insignificant effect observed in the Brazilian trial 49 may be because it utilised only self-pickup and delivery systems for kits between participants and clinic. Where participants have to attend the clinic twice to complete a screen (i.e. to pick up and drop off a kit), home sampling may not offer much advantage compared with the traditional clinic screen. Issues of privacy, distance and transport may have also contributed to the insignificant response rates observed between groups.
The four other trials that reported a significant increase in uptake were all conducted in the developed world. [58] [59] [60] [61] The factorial trial 61 explored the use of reminders alongside the intervention home sampling and observed significant increases in uptake when the analysis was conducted among all participants and limited to those reached by reminder calls. 61 It is, however, difficult to say whether it was the reminders that resulted in an increased response rate (as more calls were delivered to the women in the home group) or the strategy alone. 61 Three studies which reported on the number of rejected specimens found no statistically significant difference by allocation. 49, 57, 58 With two trials in the developing world 49, 57 and one in USA, 58 the implication is that, if well instructed, women are able to collect as adequate a specimen as clinicians for diagnosis by molecular techniques.
In relation to ease of self-sampling, more women in the home group rated self-sampling as being easy compared with the clinic group (in two trials). 49, 58 These contrast with the trial by Jones et al., 57 where more females in the clinic group rated self-sampling as easy when compared with those in the home group. 57 One possible reason for the difference observed was that participants allocated to the clinic group in this trial selfcollected specimens under supervision of the nurse. This assistance may have biased the ratings obtained in favour of the clinic group.
When asked by questionnaire and interview methods, more women in the home group were observed to exhibit a preference for resampling at home in three trials. 49, 57, 58 Exposure to home screening may have affected the response rate to be in favour of the home group. This may also infer that the strategy is acceptable to women.
The studies included in this review were judged as moderate in quality, with each having a low risk of bias in at least four domains. 49, [57] [58] [59] [60] [61] Although the review consisted of studies from different parts of the world, not all regions, cultural and ethnic groups were represented. Most of the studies were conducted in America, 58, 59, 61 only one in Africa 57 and none in Asia. The effect of the intervention may differ elsewhere. The recruitment of participants from only the clinic in one study 58 and the use of a baseline screen as a criterion for enrolment in three studies 58, 59, 61 may have introduced selection bias into the study. There is the possibility that those that consented and participated in the study may be systematically different from those that did not, thus questioning the generalisability. Furthermore, increases in uptake observed in the home sampling group may have been influenced by prior contact of study subjects with researchers at enrolment in which the screening process was described and procedural instructions provided. Hence, lower uptake levels may be observed in reallife settings where researcher-patient relationships may be nonexistent and where health care delivery mechanisms differ. For instance, a report on a 3-year registry-based screening for chlamydia in the Netherlands by van den Broek et al. 62 indicated that the use of home-based screening may not necessarily result in increased uptake over time. In that study, uptake dropped from 16% in the first year to 9% by the third year, indicating inconsistency, as opposed to the clinic group, which maintained 13% uptake levels. 62 The researchers suggested that declining participation may have been due to logistical challenges, since participants needed to log on to websites to access kits. 62 The findings in this review are similar to those observed in two traditional reviews on home-based sampling. In the review by Graseck et al. 30 and Shih et al., 46 home-based screening strategies were associated with higher utilisation rates of STI screening facilities in both sexes.
The strengths of this review include its conduct (in line with Cochrane guidance) and its choice of the RCT study design for the evaluation of screening programs. Studies are representative of recently published evidence with the majority being adequately powered and having reasonable lengths of followups. The incorporation of self-report and medical record into the assessment of outcomes in some of the trials and the grouping of outcomes as such was also another strength, making for robust data. The adoption of a statistical pooling approach, and sensitivity and subgroup analysis, as well as narrative synthesis, are also major strengths of the review.
A probable limitation was the exclusion of studies written in other languages (in need of translation), which could have introduced bias into the review findings. Second, the lack of blinding of the quality assessors to the names of the authors, institutions and journals may have influenced the risk of bias ratings of included studies. Another shortcoming is the limited number of trials reviewed on home-based sampling, which were not representative enough of all regions to allow for strong recommendations in favour of one strategy over the other.
Home-based screening has, however, shown the potential to encourage screening and treatment of the females least likely to seek care at clinics. Therefore, the strategy may be utilised as part of a multipronged approach to the control of STIs and not seen as a replacement for traditional clinic screening programs. Both strategies could, therefore, be explored as complementary arms of a full service screening program. This review has also brought to light the possible role reminders may play in improving STI screening rates in females. There is a need for more RCTs with larger sample sizes and longer study durations to be conducted in this area among females with diverse cultural and ethnic backgrounds. Cluster trials should be avoided, as they are prone to certain biases. Where utilised, a unit of analysis should be reported alongside the intracluster correlation coefficient for the trial to allow an individual-level assessment of the intervention.
New trials should present data in more transparent forms as well as explore the effect of self-reporting and medical records on uptake. Where the effect of reminders on uptake is explored, it should be done separately from the assessment of home-based sampling to enable comparison.
Conclusion
This systematic review provides modest evidence that homebased self-sampling enhances uptake of STI screening among females (aged 14-50 years) in the developed world. The evidence of its effectiveness in the developing world is, however, unclear. Both strategies had a similar effect on specimen quality.
As the evidence on effectiveness of this strategy appears to be dominated by trials in the developed world, it may serve as an alternative for women who shy away from clinics. The data are important for informing evidence-based decisions to add a home collection strategy to existing clinic-based control programs as part of a multipronged approach to enhance screening uptake in these regions. However, to further elucidate the effectiveness of this strategy and to justify its use at population-level screening, further research on the effectiveness and cost-effectiveness of the strategy is required. High quality trials with larger sample sizes and longer study durations are required both in the industrialised and developing world.
